Rigel Pharmaceuticals (RIGL) 3.56 $RIGL After H
Post# of 64072
Posted On: 03/08/2015 6:06:11 PM
Rigel Pharmaceuticals (RIGL) 3.56 $RIGL
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 24.63 (-0.10), NG: 3.26 (-0.19), CRIS: 3.04 (-0.29), EVTC: 21.77 (+0.27), GTN: 12.60 (+0.29), SM: 44.49 (-1.81), MNKD: 5.47 (-0.26), RIGL: 3.56 (+0.26), EXK: 1.96 (-0.09), WBAI: 14.50 (+0.70)
Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:10AM CST
Rigel Pharmaceuticals, Inc.'s (RIGL) fourth-quarter 2014 loss of 25 cents per share was in line with the Zacks Consensus Estimate.
AZN: 66.27 (-1.91), BMY: 65.12 (-0.93), THRX: 19.60 (-0.26), RIGL: 3.56 (+0.26)
Rigel Pharma ups revenues 48% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:14AM CST
RIGL: 3.56 (+0.26)
Rigel reports 4Q loss
Automated Insights - Tue Mar 03, 6:54AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $22.3 million in its fourth quarter.
RIGL: 3.56 (+0.26)
Rigel Pharmaceuticals beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:32AM CST
RIGL: 3.56 (+0.26)
Rigel Announces Fourth Quarter and Year End 2014 Financial Results
PR Newswire - Tue Mar 03, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.
RIGL: 3.56 (+0.26)
Rigel Pharmaceuticals (RIGL) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 6:18AM CST
Rigel Pharmaceuticals (RIGL) Shares March Higher, Can It Continue?
RIGL: 3.56 (+0.26)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:30PM CST
SSI: 20.94 (+0.19), PRIM: 17.23 (-0.29), ACW: 4.72 (-0.25), DKS: 56.44 (+0.14), TPH: 14.66 (-0.31), TEDU: 10.24 (+0.21), BBEP: 7.50 (-0.16), BBY: 39.71 (+0.08), BNS: 51.19 (-0.95), RIGL: 3.56 (+0.26), INSY: 57.69 (+0.08), AZO: 645.20 (-5.77), NAV: 29.86 (-0.44), JD: 28.62 (-0.38), KATE: 32.82 (-0.44)
Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 5:54PM CST
Bristol-Myers (BMY) is strengthening its immuno-oncology pipeline through the acquisition of Flexus Biosciences and a collaboration with Rigel Pharmaceuticals.
AGN: 233.51 (-1.90), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 26.24 (+0.27), SLXP: 158.01 (+0.57), BIOC: 3.10 (-0.26), VASC: 28.66 (-0.69), AXPW: 0.18 (-0.01), FCCY: 11.69 (+0.31), RIGL: 3.56 (+0.26), REXI: 9.05 (-0.10), HLSS: 18.42 (-0.03)
Most active Nasdaq-traded stocks
AP - Tue Feb 24, 12:17PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 28.50 (-0.78), FB: 80.00 (-1.21), DISCB: 33.59 (-1.31), SLXP: 158.01 (+0.57), DISCA: 33.08 (-0.48), BIOC: 3.10 (-0.26), CMCSK: 59.91 (+0.06), INTC: 33.19 (-0.54), RIGL: 3.56 (+0.26), FSLR: 60.61 (-1.05), DISCK: 31.77 (-0.38), CYTX: 1.11 (-0.05), MSFT: 42.36 (-0.75), AAPL: 126.60 (+0.19), CMCSA: 60.37 (+0.04), CSCO: 28.92 (-0.38), HLSS: 18.42 (-0.03)
Why Shares of Rigel Pharmaceuticals Inc. Exploded Today
Alex Planes, The Motley Fool - Motley Fool - Mon Feb 23, 12:33PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rigel Pharmaceuticals are trading more...
BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 11:44AM CST
HNH: 43.18 (-1.34), MELA: 1.83 (+0.02), CYBR: 59.78 (-3.09), OTIV: 1.24 (-0.02), CERU: 8.12 (+0.14), CLDX: 29.39 (-0.39), BIOC: 3.10 (-0.26), AXN: 1.49 (+0.37), SPPI: 6.26 (+0.02), NSLP: 7.65 (-0.05), RIGL: 3.56 (+0.26), VRTB: 3.61 (+0.30), WBAI: 14.50 (+0.70), BLCM: 24.48 (+0.13), SFY: 3.12 (-0.12), TSEM: 17.50 (-0.31), PTCT: 71.13 (-1.59), HOTR: 2.04 (-0.03), PRTA: 26.12 (-0.46), DGLY: 12.81 (+0.43)
Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies
at The Street - Mon Feb 23, 10:14AM CST
The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.
BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26), CELG: 118.03 (-2.68)
Bristol-Myers adds to cancer-treatment push with acquisition
AP - Mon Feb 23, 8:48AM CST
NEW YORK (AP) — Bristol-Myers Squibb is using an acquisition that could be worth more than $1 billion and a separate collaboration agreement to continue its push into developing cancer treatments that use a patient's immune system to attack the disease.
RIGL: 3.56 (+0.26)
Bristol-Myers and Rigal Pharma team up in cancer therapeutics
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:21AM CST
BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:14AM CST
VRX: 198.71 (-5.24), OIBR: 2.06 (-0.11), CLDX: 29.39 (-0.39), HSBC: 42.81 (-0.78), ASTI: 1.43 (-0.02), AXN: 1.49 (+0.37), SPPI: 6.26 (+0.02), BIOC: 3.10 (-0.26), NBG: 1.43 (-0.08), RIGL: 3.56 (+0.26), BLDP: 2.29 (-0.06), MHR: 2.52 (-0.13), CSC: 68.86 (-1.00), PPO: 59.23 (+0.10), GERN: 3.50 (-0.28), ACI: 1.10 (-0.02), TSEM: 17.50 (-0.31), HOTR: 2.04 (-0.03), DGLY: 12.81 (+0.43), HLSS: 18.42 (-0.03), XOMA: 3.57 (-0.08)
Lion Biotechnologies names Ryan Maynard as director and chair of Audit Committee
M2 - Wed Feb 18, 6:44AM CST
Biotechnology company Lion Biotechnologies (Other OTC:LBIO) said on Tuesday that its board of directors has elected Ryan Maynard as its director and chair of the audit committee with immediate effect.
LBIO: 9.00 (-0.56), RIGL: 3.56 (+0.26)
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
GlobeNewswire - Tue Feb 17, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately.
LBIO: 9.00 (-0.56), RIGL: 3.56 (+0.26)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STON: 28.24 (+0.09), AMRN: 1.78 (+0.11), SPRT: 1.74 (+0.03), CGEN: 8.13 (-0.14), PFH: 18.33 (-0.34), RIGL: 3.56 (+0.26)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 24.63 (-0.10), NG: 3.26 (-0.19), CRIS: 3.04 (-0.29), EVTC: 21.77 (+0.27), GTN: 12.60 (+0.29), SM: 44.49 (-1.81), MNKD: 5.47 (-0.26), RIGL: 3.56 (+0.26), EXK: 1.96 (-0.09), WBAI: 14.50 (+0.70)
Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:10AM CST
Rigel Pharmaceuticals, Inc.'s (RIGL) fourth-quarter 2014 loss of 25 cents per share was in line with the Zacks Consensus Estimate.
AZN: 66.27 (-1.91), BMY: 65.12 (-0.93), THRX: 19.60 (-0.26), RIGL: 3.56 (+0.26)
Rigel Pharma ups revenues 48% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:14AM CST
RIGL: 3.56 (+0.26)
Rigel reports 4Q loss
Automated Insights - Tue Mar 03, 6:54AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $22.3 million in its fourth quarter.
RIGL: 3.56 (+0.26)
Rigel Pharmaceuticals beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:32AM CST
RIGL: 3.56 (+0.26)
Rigel Announces Fourth Quarter and Year End 2014 Financial Results
PR Newswire - Tue Mar 03, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.
RIGL: 3.56 (+0.26)
Rigel Pharmaceuticals (RIGL) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 6:18AM CST
Rigel Pharmaceuticals (RIGL) Shares March Higher, Can It Continue?
RIGL: 3.56 (+0.26)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:30PM CST
SSI: 20.94 (+0.19), PRIM: 17.23 (-0.29), ACW: 4.72 (-0.25), DKS: 56.44 (+0.14), TPH: 14.66 (-0.31), TEDU: 10.24 (+0.21), BBEP: 7.50 (-0.16), BBY: 39.71 (+0.08), BNS: 51.19 (-0.95), RIGL: 3.56 (+0.26), INSY: 57.69 (+0.08), AZO: 645.20 (-5.77), NAV: 29.86 (-0.44), JD: 28.62 (-0.38), KATE: 32.82 (-0.44)
Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 5:54PM CST
Bristol-Myers (BMY) is strengthening its immuno-oncology pipeline through the acquisition of Flexus Biosciences and a collaboration with Rigel Pharmaceuticals.
AGN: 233.51 (-1.90), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 26.24 (+0.27), SLXP: 158.01 (+0.57), BIOC: 3.10 (-0.26), VASC: 28.66 (-0.69), AXPW: 0.18 (-0.01), FCCY: 11.69 (+0.31), RIGL: 3.56 (+0.26), REXI: 9.05 (-0.10), HLSS: 18.42 (-0.03)
Most active Nasdaq-traded stocks
AP - Tue Feb 24, 12:17PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 28.50 (-0.78), FB: 80.00 (-1.21), DISCB: 33.59 (-1.31), SLXP: 158.01 (+0.57), DISCA: 33.08 (-0.48), BIOC: 3.10 (-0.26), CMCSK: 59.91 (+0.06), INTC: 33.19 (-0.54), RIGL: 3.56 (+0.26), FSLR: 60.61 (-1.05), DISCK: 31.77 (-0.38), CYTX: 1.11 (-0.05), MSFT: 42.36 (-0.75), AAPL: 126.60 (+0.19), CMCSA: 60.37 (+0.04), CSCO: 28.92 (-0.38), HLSS: 18.42 (-0.03)
Why Shares of Rigel Pharmaceuticals Inc. Exploded Today
Alex Planes, The Motley Fool - Motley Fool - Mon Feb 23, 12:33PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rigel Pharmaceuticals are trading more...
BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 11:44AM CST
HNH: 43.18 (-1.34), MELA: 1.83 (+0.02), CYBR: 59.78 (-3.09), OTIV: 1.24 (-0.02), CERU: 8.12 (+0.14), CLDX: 29.39 (-0.39), BIOC: 3.10 (-0.26), AXN: 1.49 (+0.37), SPPI: 6.26 (+0.02), NSLP: 7.65 (-0.05), RIGL: 3.56 (+0.26), VRTB: 3.61 (+0.30), WBAI: 14.50 (+0.70), BLCM: 24.48 (+0.13), SFY: 3.12 (-0.12), TSEM: 17.50 (-0.31), PTCT: 71.13 (-1.59), HOTR: 2.04 (-0.03), PRTA: 26.12 (-0.46), DGLY: 12.81 (+0.43)
Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies
at The Street - Mon Feb 23, 10:14AM CST
The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.
BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26), CELG: 118.03 (-2.68)
Bristol-Myers adds to cancer-treatment push with acquisition
AP - Mon Feb 23, 8:48AM CST
NEW YORK (AP) — Bristol-Myers Squibb is using an acquisition that could be worth more than $1 billion and a separate collaboration agreement to continue its push into developing cancer treatments that use a patient's immune system to attack the disease.
RIGL: 3.56 (+0.26)
Bristol-Myers and Rigal Pharma team up in cancer therapeutics
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:21AM CST
BMY: 65.12 (-0.93), RIGL: 3.56 (+0.26)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:14AM CST
VRX: 198.71 (-5.24), OIBR: 2.06 (-0.11), CLDX: 29.39 (-0.39), HSBC: 42.81 (-0.78), ASTI: 1.43 (-0.02), AXN: 1.49 (+0.37), SPPI: 6.26 (+0.02), BIOC: 3.10 (-0.26), NBG: 1.43 (-0.08), RIGL: 3.56 (+0.26), BLDP: 2.29 (-0.06), MHR: 2.52 (-0.13), CSC: 68.86 (-1.00), PPO: 59.23 (+0.10), GERN: 3.50 (-0.28), ACI: 1.10 (-0.02), TSEM: 17.50 (-0.31), HOTR: 2.04 (-0.03), DGLY: 12.81 (+0.43), HLSS: 18.42 (-0.03), XOMA: 3.57 (-0.08)
Lion Biotechnologies names Ryan Maynard as director and chair of Audit Committee
M2 - Wed Feb 18, 6:44AM CST
Biotechnology company Lion Biotechnologies (Other OTC:LBIO) said on Tuesday that its board of directors has elected Ryan Maynard as its director and chair of the audit committee with immediate effect.
LBIO: 9.00 (-0.56), RIGL: 3.56 (+0.26)
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
GlobeNewswire - Tue Feb 17, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately.
LBIO: 9.00 (-0.56), RIGL: 3.56 (+0.26)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: STON: 28.24 (+0.09), AMRN: 1.78 (+0.11), SPRT: 1.74 (+0.03), CGEN: 8.13 (-0.14), PFH: 18.33 (-0.34), RIGL: 3.56 (+0.26)
(0)
(0)Scroll down for more posts ▼